7:00 AM ET
8-K
Clinical Trial Data
Immix Biopharma Clinical Trial Data
Immix Biopharma announced positive interim results from its Phase 2 NEXICART-2 clinical trial of NXC-201 in relapsed/refractory AL Amyloidosis, showing an 89% complete response rate across 45 patients. The company noted that MRD-negativity predicts future complete responses, potentially increasing the rate to 98%, and plans a BLA submission for the therapy in mid-2027.
- Earnings call
- Sep 29, 2026, 8:00 AM ET